Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 6/20 | 0.59 |
| ▸ | MDM4 | O15151 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TNF | P01375 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29528770 | 0.90 | MDM4 (0.59) | TLR2MDM4TP53KMT2AMDM2 | |
| SCHEMBL119688 | 0.90 | MDM4 (0.59) | TLR2MDM4TP53KMT2AMDM2 | |
| SCHEMBL31276348 | 0.90 | MDM4 (0.59) | TLR2MDM4TP53KMT2AMDM2 | |
| SCHEMBL5967446 | 0.90 | MDM4 (0.59) | TLR2MDM4TP53KMT2AMDM2 | |
| SCHEMBL119637 | 0.90 | MDM4 (0.59) | TLR2MDM4TP53KMT2AMDM2 | |
| SCHEMBL29455664 | 0.90 | MDM4 (0.59) | TLR2MDM4TP53KMT2AMDM2 | |
| SCHEMBL4600667 | 0.90 | TLR2 (0.60) | TLR2MDM4TP53TNFKMT2A | |
| SCHEMBL4600248 | 0.89 | TLR2 (0.59) | TLR2MDM4TP53TNFKMT2A | |
| SCHEMBL8354047 | 0.88 | TLR2 (0.58) | TLR2MDM4TP53TNFKMT2A | |
| SCHEMBL15806918 | 0.87 | MDM4 (0.56) | TLR2MDM4TP53TNFKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1135374-B9 | BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| EP-1135374-B1 | BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1135374-A1 | BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6204282-B1 | TREATING CANCER, RETINOPATHY, ATHEROSCLEROSIS, VASCULAR RESTENOSIS, OR OSTEOPOROSIS. | SCHERING CORPORATION | 2001-03-20 | — | — | US | disclosed |
| WO-2000032578-A1 | BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | TLR2 2757/4885MDM4 934/4885TP53 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.